EVA; A novel therapeutic targeting Rationale for the Treatment of Glioblastoma.

被引：0
|
作者：
Rusch, Tillmann [1 ]
Zhao, Kai [2 ]
Neubauer, Andreas [1 ]
Nimsky, Christopher [2 ]
Bartsch, Joerg [2 ]
机构：
[1] UKGM Giessen & Marburg, Standort Marburg, Klin Hamatol Onkol & Immunol, Marburg, Germany
[2] UKGM Giessen & Marburg, Standort Marburg, Klin Neurochirurgie, Marburg, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P16-10
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [21] Age at diagnosis and type of treatment in elderly patients with glioblastoma.
    Williams, V. L.
    Stockwell, H.
    Shahani, D.
    Chamberlain, M.
    Sloan, A.
    Barnholtz-Sloan, J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : S92 - S92
  • [22] Targeting FASN improves type I interferon responses in irradiated glioblastoma.
    De Martino, Mara
    Daviaud, Camille
    Vanpouille-Box, Claire
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [23] Targeting androgen receptor signaling in glioblastoma: A novel biomarker and therapeutic approach
    Mason, Sofia
    Chung, Sylvia
    Juan, Beatriz Perez San
    McCool, Cerys
    Day, Bryan
    Milioli, Heloisa Zaccaron
    Dear, Rachel Fitz-Gerald
    Sim, Hao-Wen
    Holst, Jeff
    Chaffer, Christine Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma
    Yanfei Sun
    Guangjing Mu
    Zhiwei Xue
    Xingang Li
    Xiaoying Lin
    Mingzhi Han
    Journal of Translational Medicine, 21
  • [25] Patient-specific mathematical modeling as a precision-medicine approach to evaluating therapeutic gains of a novel chemoprotection treatment in newly diagnosed glioblastoma.
    Johnston, Sandra K.
    Adair, Jennifer E.
    Bridge, Carly
    Guyman, Laura
    Hawkins-Daarud, Andrea
    Rockne, Russell
    Baldock, Anne
    Rockhill, Jason K.
    Mrugala, Maciej M.
    Beard, Brian C.
    Kiem, Hans-Peter
    Swanson, Kristin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Mechanistic and therapeutic links between purine biosynthesis and DNA damage in glioblastoma.
    Scott, Andrew J.
    Zhou, Weihua
    Wilder-Romans, Kari
    Andren, Anthony C.
    Zhang, Li
    Umemura, Yoshie
    Qi, Nathan
    Lawrence, Theodore S.
    Lyssiotis, Costas A.
    Wahl, Daniel R.
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [27] Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    de Groot, John
    Milano, Vanessa
    JOURNAL OF NEURO-ONCOLOGY, 2009, 95 (02) : 151 - 163
  • [28] Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
    Mecca, Carmen
    Giambanco, Ileana
    Donato, Rosario
    Arcuri, Cataldo
    DISEASE MARKERS, 2018, 2018
  • [29] Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    John de Groot
    Vanessa Milano
    Journal of Neuro-Oncology, 2009, 95 : 151 - 163
  • [30] Targeting the stem cell factor HMGA2 to improve outcomes in glioblastoma.
    Kaur, Harpreet
    Hutt, Marianne
    Mao, Xing-gang
    Eberhart, Charles G.
    Raabe, Eric H.
    CANCER RESEARCH, 2013, 73 (08)
12345